| New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C (NCT01888900) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2013-05-01 |
| Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients (NCT01858961) | Boehringer Ingelheim | 2013-05-01 |
| A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis (NCT01749150) | Hoffmann-La Roche | 2013-04-01 |
| Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants (NCT01849562) | Alexion Pharmaceuticals, Inc. | 2013-04-01 |
| BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3 (NCT01830127) | Boehringer Ingelheim | 2013-04-01 |
| Combination Therapy for Chronic Hepatitis C Infection (NCT01805882) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-01-01 |
| Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) (NCT01606800) | Merck Sharp & Dohme LLC | 2013-01-01 |
| DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) (NCT01743521) | Kirby Institute | 2013-01-01 |
| Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir (NCT01818856) | Hospitales Universitarios Virgen del Rocío | 2012-12-01 |
| IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1 (NCT01732796) | Boehringer Ingelheim | 2012-12-01 |
| An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients (NCT01725529) | Janssen R&D Ireland | 2012-11-01 |
| An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure (NCT01798576) | Hoffmann-La Roche | 2012-11-01 |
| Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 (NCT01728324) | Boehringer Ingelheim | 2012-11-01 |
| 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study (NCT02465203) | Novartis Pharmaceuticals | 2012-09-06 |
| A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection (NCT01608737) | Boehringer Ingelheim | 2012-09-01 |
| A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C (NCT01591460) | Hoffmann-La Roche | 2012-08-01 |
| A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (NCT01685203) | AbbVie (prior sponsor, Abbott) | 2012-08-01 |
| Dose Ranging of GSK2336805 in Combination Therapy (NCT01648140) | GlaxoSmithKline | 2012-08-01 |
| A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment (NCT01579019) | Hoffmann-La Roche | 2012-07-01 |
| Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients (NCT01636778) | GlaxoSmithKline | 2012-07-01 |
| Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2) (NCT01760148) | Junqi Niu | 2012-07-01 |
| An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 (NCT01750216) | Hoffmann-La Roche | 2012-07-01 |
| Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV (NCT02690103) | Cairo University | 2012-07-01 |
| An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection (NCT01671046) | Hoffmann-La Roche | 2012-07-01 |
| ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment (NCT01628094) | Hoffmann-La Roche | 2012-06-01 |
| A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (NCT01364090) | Kirby Institute | 2012-06-01 |
| Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa (NCT02439918) | Université de Sherbrooke | 2012-06-01 |
| Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) (NCT01544920) | Merck Sharp & Dohme LLC | 2012-05-30 |
| An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (NCT01604291) | Hoffmann-La Roche | 2012-05-28 |
| Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518) (NCT01544582) | Merck Sharp & Dohme LLC | 2012-05-01 |
| Gilead Sustained Virologic Response (SVR) Registry (NCT01457755) | Gilead Sciences | 2012-04-13 |
| Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients (NCT01525628) | Boehringer Ingelheim | 2012-04-01 |
| A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002) (NCT01554189) | Merck Sharp & Dohme LLC | 2012-04-01 |
| A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis (NCT01483742) | Hoffmann-La Roche | 2012-04-01 |
| Drug-drug Interaction of BI 201335 and Microgynon (NCT01570244) | Boehringer Ingelheim | 2012-04-01 |
| This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C (NCT01528735) | Boehringer Ingelheim | 2012-02-01 |
| An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1 (NCT01508130) | Hoffmann-La Roche | 2012-01-31 |
| Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001) (NCT01508156) | Merck Sharp & Dohme LLC | 2012-01-01 |
| Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation (NCT01579162) | HepQuant, LLC | 2012-01-01 |
| A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) (NCT01585324) | Hoffmann-La Roche | 2012-01-01 |
| First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (NCT01554085) | Alios Biopharma Inc. | 2011-12-31 |
| First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (NCT01590407) | Alios Biopharma Inc. | 2011-12-31 |
| A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response (NCT01457768) | Gilead Sciences | 2011-12-19 |
| An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis (NCT01609049) | Hoffmann-La Roche | 2011-12-07 |
| Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) (NCT01440595) | Merck Sharp & Dohme LLC | 2011-11-28 |
| A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C (NCT01482403) | Hoffmann-La Roche | 2011-11-01 |
| Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype (NCT01459913) | Vertex Pharmaceuticals Incorporated | 2011-11-01 |
| Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) (NCT01390844) | Merck Sharp & Dohme LLC | 2011-10-21 |
| Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection (NCT01587586) | PharmaEssentia | 2011-10-18 |
| A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients (NCT01523990) | TaiGen Biotechnology Co., Ltd. | 2011-10-01 |
| Prediction of Liver-related Outcomes After HCV Cure (NCT04460157) | Hospital Universitario de Valme | 2011-10-01 |
| A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1 (NCT01448200) | Presidio Pharmaceuticals, Inc. | 2011-10-01 |
| Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045) (NCT01405560) | Merck Sharp & Dohme LLC | 2011-09-02 |
| GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection (NCT01435226) | Gilead Sciences | 2011-09-01 |
| An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C (NCT01447446) | Hoffmann-La Roche | 2011-09-01 |
| Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir (NCT02113631) | Louis Stokes VA Medical Center | 2011-09-01 |
| Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4) (NCT01399619) | Boehringer Ingelheim | 2011-09-01 |
| Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (NCT01435044) | Gilead Sciences | 2011-09-01 |
| Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044) (NCT01405937) | Merck Sharp & Dohme LLC | 2011-08-29 |
| A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C (NCT01675427) | Hoffmann-La Roche | 2011-08-01 |
| Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects (NCT01439373) | GlaxoSmithKline | 2011-07-07 |
| GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus (NCT01356160) | Gilead Sciences | 2011-07-01 |
| The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients (NCT01770483) | Services Institute of Medical Sciences, Pakistan | 2011-07-01 |
| Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) (NCT01371604) | Merck Sharp & Dohme LLC | 2011-07-01 |
| Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (NCT01371578) | Gilead Sciences | 2011-07-01 |
| Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043) (NCT01370642) | Merck Sharp & Dohme LLC | 2011-06-27 |
| Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3) (NCT01358864) | Boehringer Ingelheim | 2011-06-01 |
| A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C (NCT01705717) | Hoffmann-La Roche | 2011-06-01 |
| An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin (NCT01392742) | Hoffmann-La Roche | 2011-05-31 |
| A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection (NCT01366638) | Janssen Pharmaceutical K.K. | 2011-05-01 |
| A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C (NCT01331850) | Hoffmann-La Roche | 2011-05-01 |
| Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C (NCT02309086) | Clinica Universidad de Navarra, Universidad de Navarra | 2011-05-01 |
| A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C (NCT01659567) | Hoffmann-La Roche | 2011-04-06 |
| The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients (NCT01335230) | University of Cincinnati | 2011-04-01 |
| Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen (NCT01332955) | ANRS, Emerging Infectious Diseases | 2011-04-01 |
| A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy (NCT01337375) | Hoffmann-La Roche | 2011-03-01 |
| Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 (NCT01329978) | Gilead Sciences | 2011-03-01 |
| A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR) (NCT01278134) | Hoffmann-La Roche | 2011-02-01 |
| A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) (NCT01447420) | Hoffmann-La Roche | 2011-02-01 |
| A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy (NCT01288209) | Janssen Pharmaceutical K.K. | 2011-02-01 |
| A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients (NCT01292239) | Janssen Pharmaceutical K.K. | 2011-02-01 |
| Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes (NCT01226797) | Pfizer | 2011-01-17 |
| An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C (NCT03423641) | Kaiser Permanente | 2011-01-01 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection (NCT01316237) | Gilead Sciences | 2011-01-01 |
| A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy (NCT01290731) | Janssen Pharmaceutical K.K. | 2011-01-01 |
| Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients (NCT01758939) | Cairo University | 2011-01-01 |
| A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C (NCT01903954) | Hoffmann-La Roche | 2011-01-01 |
| Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C (NCT01900886) | Grupo de Enfermedades Infecciosas de la Sociedad Española de Sanidad Penitenciaria | 2010-12-01 |
| A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection (NCT01220947) | Hoffmann-La Roche | 2010-11-01 |
| Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4 (NCT01884402) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2010-10-01 |
| A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (NCT01271790) | Gilead Sciences | 2010-10-01 |
| An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens (NCT01168856) | Hoffmann-La Roche | 2010-09-01 |
| Prospective Observational Study of Disease Progression in Chronic Hepatitis C (NCT02011932) | Beijing YouAn Hospital | 2010-07-01 |
| The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System (NCT01206933) | George Washington University | 2010-07-01 |
| Biliverdin Reductase A in Chronic Hepatitis C Virus Infection (NCT01112033) | Charles University, Czech Republic | 2010-06-01 |
| To Study the Efficacy and Safety of Renessans in Chronic HCV Patients (NCT01463592) | MTI Medical Private Limited, Pakistan | 2010-06-01 |
| Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection (NCT01001754) | ZymoGenetics | 2010-05-01 |
| Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (NCT01132313) | Boehringer Ingelheim | 2010-05-01 |
| An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy (NCT01416610) | Hoffmann-La Roche | 2010-04-01 |
| VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo (NCT01054573) | Janssen Infectious Diseases BVBA | 2010-04-01 |